The content on this website is intended solely for veterinarians and other animal health professionals.
By using this website, you confirm that the above applies to you.
Intervacc receives positive CVMP opinion for Strangvac, a vaccine against equine strangles, in the EU
Stockholm, June 17, 2021 – Intervacc AB (“Intervacc”) announced today that the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending approval of Strangvac® within the EU....Report from Annual General Meeting in Intervacc
Intervacc AB (publ) has held its Annual General Meeting (”AGM”) on Wednesday 9 June 2021, at which the following resolutions were made. Due to the continued spread of the coronavirus and the authorities’ regulations/advice on avoiding public gatherings, the Annual...CEO presentation AGM
This years AGM will be held June 9th 2021 without physical presence of shareholders and shareholder can only can exercise their voting rights by postal voting. A presentation by CEO Andreas Andersson, where he comment upon the Company’s activities during the...Intervacc and the Karolinska Institutet sign a multi-year contract for the development of innovative animal health vaccines
Stockholm May 28, 2021 – Intervacc AB (publ) and the Karolinska Institute, KI, announce today that they have extended the contract for the development of a new generation of animal health vaccines using recombinant proteins. The three-year contract means that...Nyhetstjänster
